Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

The role of KRAS in the emergence of drug tolerance in lung cancer

A postgraduate research opportunity at the University of Otago.

Details

Academic background
Sciences, Health Sciences
Host campus
Dunedin
Qualifications
Postgraduate Diploma, Honours, Master’s
Department
Pathology (Dunedin)
Supervisors
Dr Glen Reid, Dr Cath Drummond

Overview

Mutant forms of the oncogene KRAS are common drivers of non-small cell lung cancers (NSCLC).

Recently, sotorasib and adagrasib – targeted agents that specifically inhibit the KRASG12C mutant – have been approved for treating patients. Unfortunately, while many respond to this therapy, resistance invariably occurs.

This project will investigate how variable KRAS expression levels in different subpopulations of NSCLC cells contribute to their initial survival when treated with KRAS inhibitors.

Contact

Glen Reid
Email   glen.reid@otago.ac.nz